Experimental studies of tumor immunotherapy. I. Macrophage migration inhibitory activity as an immunological parameter.
The macrophage migration inhibition activity [MI activity) was stable in sensitized lymphocyte-to-marcophage ratios of 1:5 to 1:20 in mice. Antigen protein concentrations under 100 mug/ml did not induce nonspecific macrophage migration inhibition. Inhibition of tumor proliferation and survival was observed after a combined injection of BCG and MH-134 cells. After a single injection of MH-134 tumor cells, MI activity was reinforced and prolonged, demonstrating the clear effects of BCG as adjuvant. In DDS mice MI activity was weakened in the regional lymph node after a subcutaneous injection of just above or below 10(5) Ehrlich cancer cells previously treated with mitomycin C. This finding suggests the presence of an optimal tumor antigen concentration.
D000818:Animals; D000951:Antigens, Neoplasm; D001500:BCG Vaccine; D002464:Cell Migration Inhibition; D007111:Immunity, Cellular; D008264:Macrophages / Q000276:immunology*; D051379:Mice; D008809:Mice, Inbred C3H; D009163:Mycobacterium bovis / Q000276:immunology; D009374:Neoplasms, Experimental / Q000276:immunology*; D014181:Transplantation Immunology
D000951:Antigens, Neoplasm; D001500:BCG Vaccine